Liverpool School of Tropical Medicine (LSTM) are asking for volunteers to come forward to take part in their latest trials.
They are working on developing a vaccine for Middle Eastern Respiratory Syndrome (MERS), which is a viral infection.
MERS has no vaccine, and has infected over 2,000 people in past outbreaks. The demographic for this study is 50-70 year olds and participants will receive a maximum of £360 for taking part.
LSTM are also recruiting people for the BCG CHIM study, which is a feasibility study of controlled human infection. The study aims to transfer a safe and established model of TB (Tuberculosis) controlled human infection from collaborators in Oxford to LSTM.
The model uses the licensed live BCG vaccine as the infection agent, (the agent that causes the infection for example bacteria or a virus) and participants are followed up to monitor their immune response. On Day 14 participants undertake a skin biopsy to assess if the live BCG is continuing to grow in the skin after injection.
The demographic for this study is healthy adults aged 18-50 who are in good health and live in the Merseyside area. The trial has two Phases: A and B with each providing a separate reimbursement. Participants will receive £320 for completing Phase A and £370 for Phase B.
Paula Sanderson, the Senior Trial Manager at Liverpool Vaccine Group, spoke to MerseyNewsLive more about their current studies.
Listen to our report here:
- If you want to hear more or get involved with medical trials at Liverpool School of Tropical Medicine you can text 07740 410 290.
Featured image (c) Abigail Ford
